The SKILL Card test in optic neuritis: experience of the Optic Neuritis Treatment Trial. Smith-Kettlewell Institute Low Luminance. Optic Neuritis Study Group.
OBJECTIVE
To assess the value of the Smith-Kettlewell Institute Low Luminance (SKILL) Card test, designed to measure vision at reduced contrast and luminance, among patients with previous optic neuritis.


METHODS
The SKILL Card test was administered to 295 patients participating in the Optic Neuritis Treatment Trial (ONTT) follow-up study, concurrent with measurement of visual acuity, visual field, contrast sensitivity, and color vision. Health-related quality of life (HRQL) was also assessed in a subset of patients using the National Eye Institute Visual Function Questionnaire and an ONTT-developed questionnaire.


RESULTS
The SKILL Card difference score (high-contrast acuity score minus low-contrast acuity score) was only weakly associated with the other measures of vision function (rs absolute range, 0.05-0.31) and with the HRQL measures (rs absolute range, 0.02-0.15). In contrast, the light and dark component scores of the SKILL Card test had higher associations with the other vision measures (rs absolute range, 0.27-0.54) and with the HRQL measures (rs absolute range, 0.10-0.40).


CONCLUSIONS
The SKILL Card difference score is not a meaningful measure for patients with optic neuritis; however, the test appears to have clinical usefulness as a method to measure high-contrast and low-contrast acuity.
Long
D T
DT
Jaeb Center for Health Research, Tampa, Florida 33613, USA.
Beck
R W
RW
Moke
P S
PS
Blair
R C
RC
Kip
K E
KE
Gal
R L
RL
Katz
B J
BJ
D000293:Adolescent; D000328:Adult; D015350:Contrast Sensitivity / Q000502:physiology; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006305:Health Status Indicators; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000503:physiopathology; D009902:Optic Neuritis / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D011788:Quality of Life; D011795:Surveys and Questionnaires; D014786:Vision Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000503:physiopathology; D014787:Vision Tests / Q000295:instrumentation / Q000379:methods*; D014792:Visual Acuity / Q000502:physiology; D014794:Visual Fields / Q000502:physiology
D005938:Glucocorticoids; D011241:Prednisone